Acting Health Officer Dr. Navina Baba and Director of Health Dr. Grant Colfax updated the Health Commission on monkeypox response and COVID‑19 metrics as Pride events approached.
Dr. Baba said the department activated an incident management team earlier in the month to coordinate prevention, culturally reflective messaging and clinical readiness. “We do have an incident management team working on the monkeypox issue, and that’s been activated since the beginning of this month,” she said, and reported case counts: global confirmed cases about 2,580, U.S. about 142, California 37 and San Francisco 7. She said the majority of cases in non‑endemic countries have been among cis men who have sex with men and described outreach focused on those networks, including vaccine access for post‑exposure prophylaxis at three sites and a public awareness campaign linked from sf.gov/monkeypox.
Director Colfax presented COVID‑19 surveillance: a recent case rate of about 49.8 per 100,000 (noting home tests are not included in that count), hospitalizations stable but elevated (roughly 85–100 in recent weeks), and cumulative case and death totals. He flagged the new pediatric vaccine authorization for children 6 months to 4 years and said approximately 40,000 children in that age group are eligible; distribution will rely primarily on pediatricians and the city’s vaccine sites.
Commissioners asked about tracking uptake of additional booster doses and how pediatric vaccination demand and supply will be matched to avoid waste. Dr. Baba and Dr. Colfax said the department is building datasets to monitor fourth‑dose uptake and will provide technical guidance to clinicians; they also emphasized individual clinician consultations and FAQs to address hesitancy and operational barriers.
No regulatory actions were taken during this information session while the commission briefly lost quorum, but the department said it will continue community outreach and monitoring through Pride events.